Pharma Reviews: Analysis: For pharma stocks, the fall may not be done yet

So, the bearish action of investors in India ahead of the Q4 results of pharma companies is natural. With a drop of 6 per cent this year so far, the ET ...
Read more: Analysis: For pharma stocks, the fall may not be done yet